search for


Evaluation of RF300 for Leukoreduction of Red Blood Cells
적혈구제제용 백혈구제거필터 RF300의 성능평가
The Korean Society of Blood Transfusion 2012;23:13−19
Published online April 30, 2012
© 2012 The Korean Society of Blood Transfusion.

So-Yong Kwon1, Nam-Sun Cho1, Sun Nyeo Song2, Ju Yeon Lee2, A Hyun Lim2, Hyeon Mi Lee3, Yeong Cheon Ji3, Chang Sik Seo3, Yun Hui Park3
Background:Use of universal leukoreduction for prevention of leukocyte associated transfusion reactions is common practice in many countries. This study was conducted in order to evaluate the performance of a newly developed leukoreduction filter for red blood cells (RBCs), the RF300 (Kolon Industries, Inc, Gumi, Korea).
Methods:Filtration time, RBC recovery, residual leukocyte count, and leukocyte removal rate were evaluated. To assess the quality of RBCs after filtration, percent hemolysis was monitored for a period of 21 days. Performance of the RF300 (N=78) was compared with that of the Bio-R O2 plus (Fresenius, Hamburg, Germany), the Pall Purecell RC (Pall Co., Washington, USA), and the Sepacell R-500N (Asahi, Tokyo, Japan).
Results:The shortest filtration time was observed using the RF300 (P<0.05). Using the RF300, recovery of RBC was 96.5%, which was higher than that of two filters (P<0.05). Mean residual leukocyte count was 0.26×106/unit, with a leukocyte removal rate of 3 log. Using the RF300, mean percent hemolysis was 0.32% at day 21, which was comparable with that of two filters, but lower than that of one filter (P<0.05).
Conclusion:The RF300 meets all established quality requirements for conduct of safe and effective leukoreduction of RBCs. (Korean J Blood Transfus 2012;23: 0-19)
Keywords : RF300, Leukoreduction, Red blood cells

April 2021, 32 (1)
Full Text(PDF) Free

Social Network Service

Cited By Articles
  • CrossRef (0)